Can antivirals tame a deadly Tick-Borne virus?
NCT ID NCT06860334
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This trial tests whether two antiviral drugs, favipiravir and ribavirin, can help clear the virus faster in adults hospitalized with Crimean-Congo hemorrhagic fever (CCHF), a severe tick-borne infection. Participants will receive one of the drugs or optimized standard care, and researchers will compare how quickly the virus disappears from the blood and whether serious complications are reduced. The study aims to provide the first robust evidence for treatments that are currently based on supportive care alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Favipiravir and ribavirin, antiviral drugs, compared against optimized standard of care
- What this could lead to
- If effective, these antivirals could become the first evidence-based treatments for Crimean-Congo hemorrhagic fever, potentially reducing severe illness and death.
- What could go wrong
- This is a phase IIb trial, so results are preliminary. The drugs may not improve viral clearance or outcomes, and safety risks are still being assessed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRIMEAN-CONGO HEMORRHAGIC FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atatürk University
RECRUITINGErzurum, Turkey (Türkiye)
-
Ondokuz Mayıs University
RECRUITINGSamsun, Turkey (Türkiye)
-
Sivas Cumhuriyet University
RECRUITINGSivas, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.